Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
MeSH terms: Carcinoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Laryngeal Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Verrucous; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Paranasal Sinus Neoplasms; Neoplasms, Unknown Primary; Tongue Neoplasms; Laryngeal Diseases; Recurrence
Intervention: saracatinib; laboratory biomarker analysis
Intervention description: Given PO; Correlative studies
Intervention MeSH terms: Saracatinib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 9.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase II trial is studying the how well saracatinib works in treating patients with
      metastatic or recurrent head and neck cancer. Saracatinib may stop the growth of tumor cells
      by blocking some of the enzymes needed for cell growth
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and neck

               -  Persistent, recurrent, or metastatic disease that is not amenable to
                  curative-intent therapy with surgery or radiation

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) ≥ 20 mm with conventional
             techniques or ≥ 10 mm with spiral computed tomography (CT) scan

          -  Karnofsky performance status ≥ 60%

          -  White blood cell (WBC) ≥ 3,000/mcL

          -  Absolute neutrophil count ≥ 1,500/mcL

          -  Platelets ≥ 100,000/mcL

          -  Hemoglobin > 9 g/dL

          -  Total bilirubin within upper institutional limits of normal (ULN)

          -  Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) ≤ 2.5 x ULN

          -  Creatinine within ULN OR creatinine clearance ≥ 60 mL/min

          -  Patients must agree to use adequate birth control for the duration of study
             participation and for at least 8 weeks after discontinuation of study drug

          -  May have received 1 prior cytotoxic chemotherapy regimen for recurrent or metastatic
             disease

        Exclusion Criteria:

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to AZD0530

          -  Urine protein: creatinine ratio ≥ 1.0 OR 24-hour urine protein ≥ 1,000 mg

          -  QTc prolongation ≥ 480 msecs

          -  Intercurrent symptomatic congestive heart failure, unstable angina pectoris, or
             cardiac arrhythmia

          -  History of myocardial infarction within the past year

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or breastfeeding women

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy

          -  Pulmonary fibrosis ≥ grade 2, pleural effusion (non-malignant) ≥ grade 2, or
             pneumonitis/pulmonary infiltrates ≥ grade 2

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study

          -  Patients who have not recovered from adverse events due to agents administered more
             than 4 weeks earlier

          -  Use of specifically prohibited cytochrome P450 3A4 (CYP3A4)-active agents or
             substances

               -  Prohibited drugs should be discontinued 7 days prior to the administration of the
                  first dose of AZD0530 and for 7 days following discontinuation of AZD0530

          -  Patients receiving any other investigational agents